SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-23-038042
Filing Date
2023-08-03
Accepted
2023-08-03 16:20:44
Documents
77
Period of Report
2023-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q qncx-20230630.htm   iXBRL 10-Q 3691555
2 EX-10.1 qncx-ex10_1.htm EX-10.1 20453
3 EX-31.1 qncx-ex31_1.htm EX-31.1 17443
4 EX-31.2 qncx-ex31_2.htm EX-31.2 17409
5 EX-32.1 qncx-ex32_1.htm EX-32.1 13202
6 EX-32.2 qncx-ex32_2.htm EX-32.2 13205
  Complete submission text file 0000950170-23-038042.txt   12920967

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT qncx-20230630_pre.xml EX-101.PRE 399212
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT qncx-20230630.xsd EX-101.SCH 63323
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT qncx-20230630_def.xml EX-101.DEF 247497
10 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT qncx-20230630_lab.xml EX-101.LAB 524295
11 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT qncx-20230630_cal.xml EX-101.CAL 59187
71 EXTRACTED XBRL INSTANCE DOCUMENT qncx-20230630_htm.xml XML 2864150
Mailing Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080
Business Address 601 GATEWAY BOULEVARD, SUITE 1250 SOUTH SAN FRANCISCO CA 94080 415-910-5717
Quince Therapeutics, Inc. (Filer) CIK: 0001662774 (see all company filings)

IRS No.: 901024039 | State of Incorp.: CA | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38890 | Film No.: 231140383
SIC: 2836 Biological Products, (No Diagnostic Substances)